– July 1, 2008
July 1, 2008
View Issues
-
Diabetes and Pancreatic Cancer
Patients with both DM and PaC could not be differentiated on the basis of tumor size or clinical stage. -
Lenalidomide Has Activity in CLL
Lenalidomide is an immunomodulatory oral thalidomide derivate with activity in a variety of hematologic malignancies. Ferrajoli and colleagues explored lenalidomide at a starting dose of 10mg daily without interruption for relapsed and refractory CLL. -
HER-2 Status and Prognosis in Breast Cancer Patients with Brain Metastases
A retrospective analysis of newly-diagnosed brain metastases in patients with breast cancer revealed that those with HER-2 positive disease had more favorable survival than those who were HER-2 negative. Compared to those with "triple negative" disease (median survival 4.0 months) those who had HER-2 positive disease survived 17.1 months. -
Isolated Hepatic Perfusion for Colorectal Liver Metastases
In a series of 154 patients taken to surgery for isolated hepatic perfusion to treat unresectable liver metastases, the hepatic response rate was 50% and the median progression-free and overall survival was 7.4 and 24.8 months, respectively. -
Pharmacology Watch
Shingles vaccine added to CDC list of vaccines for adults 60 and older; CDC recommends Tdap for postpartum women; new study suggests sequential therapy with antibiotics for H. pylori may be more effective than standard therapy; FDA Actions. -
Clinical Briefs in Primary Care supplement